发明名称 |
PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF HBV INFECTION |
摘要 |
First, the present inventors assessed the effect of the compound represented by formula (III) below on Huh-7 cells infected with HBV, and demonstrated that the compound alone had an anti-HBV effect in vitro. Then, the present inventors revealed that the HBV replication-suppressing effect of PEG-IFN is enhanced in chimeric mice having a human liver infected with genotype C or A HBV when PEG-IFN is used in combination with the compound represented by formula (III) above. The present inventors also revealed that the HBV replication-suppressing effect of Entecavir is enhanced in chimeric mice having a human liver infected with genotype C HBV (wild-type and Entecavir-resistant strains) when Entecavir is used in combination with the compound represented by formula (III) above. In addition, the present inventors revealed that the compound represented by formula (III) above exerts the anti-HBV effect not only against wild-type HBV strains but also against Entecavir- and/or Lamivudine-resistant HBV strains. |
申请公布号 |
EP2305234(A1) |
申请公布日期 |
2011.04.06 |
申请号 |
EP20090766696 |
申请日期 |
2009.06.18 |
申请人 |
PUBLIC UNIVERSITY CORPORATION NAGOYA CITY UNIVERSITY;CHUGAI SEIYAKU KABUSHIKI KAISHA |
发明人 |
MIZOKAMI, MASASHI;TANAKA, YASUHITO;SUGIYAMA, MASAYA;SUDOH, MASAYUKI |
分类号 |
A61K31/165;A61K31/201;A61K31/381;A61K31/405;A61K31/4406;A61K31/4418;A61P1/16;A61P31/14;A61P35/00 |
主分类号 |
A61K31/165 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|